NAPHCON FORTE
Clinical safety rating: caution
Comprehensive clinical and safety monograph for NAPHCON FORTE (NAPHCON FORTE).
Naphazoline acts as an agonist at alpha-adrenergic receptors in the vascular smooth muscle of the conjunctiva, causing vasoconstriction and reducing redness.
| Metabolism | Metabolized in the liver via oxidative deamination. |
| Excretion | Renal excretion of unchanged drug (65%) and metabolites (35%); less than 1% fecal. |
| Half-life | Terminal elimination half-life is 9-11 hours; clinically, steady state is reached after 2-3 days of regular dosing. |
| Protein binding | Approximately 85% bound to plasma proteins, primarily albumin. |
| Volume of Distribution | Vd approximately 2.0 L/kg; indicates extensive distribution into body tissues. |
| Bioavailability | Topical ophthalmic: systemic absorption is minimal (<10%) due to local administration and dilution by tears. |
| Onset of Action | Topical ophthalmic: 5-10 minutes. |
| Duration of Action | Topical ophthalmic: 6-8 hours; may require q.i.d. dosing for sustained effect. |
1-2 drops of 0.1% solution in the affected eye(s) every 3-4 hours as needed.
| Dosage form | SOLUTION/DROPS |
| Renal impairment | No dose adjustment required. |
| Liver impairment | No dose adjustment required. |
| Pediatric use | 1 drop of 0.1% solution in the affected eye(s) every 3-4 hours as needed for children ≥6 years; for children <6 years, use only under medical supervision. |
| Geriatric use | No specific dose adjustment; monitor for systemic effects due to potential increased sensitivity. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for NAPHCON FORTE (NAPHCON FORTE).
| Breastfeeding | Naphazoline is excreted in human milk in unknown amounts. M/P ratio not determined. Due to potential for systemic absorption and adverse effects (e.g., bradycardia, hypertension) in the infant, caution is advised. Use only if clearly needed, and monitor infant for signs of sympathomimetic stimulation. |
| Teratogenic Risk | Pregnancy Category C. Naphazoline, an imidazoline derivative, has not been studied in pregnant women. In animal studies, no teratogenic effects were observed at doses up to 24 mg/kg/day (oral) in rats and rabbits. However, systemic absorption from ophthalmic use is minimal, but potential fetal risks are unknown. First trimester: Use only if clearly needed; no specific teratogenic data. Second and third trimesters: May cause maternal hypertension or bradycardia with systemic absorption, but no direct fetal effects reported. Labor and delivery: Not evaluated. |
■ FDA Black Box Warning
None.
| Serious Effects |
Hypersensitivity to naphazoline or any component of the formulation; narrow-angle glaucoma; children under 6 years of age (for this concentration).
| Precautions | Prolonged use may cause rebound hyperemia. Use with caution in patients with cardiovascular disease, hypertension, hyperthyroidism, diabetes, or angle-closure glaucoma. |
Loading safety data…
| Fetal Monitoring | Monitor maternal blood pressure and heart rate, especially if used frequently or in large doses. Assess for ocular irritation or systemic effects (e.g., tachycardia, hypertension). Fetal monitoring not routinely indicated due to minimal systemic absorption. In cases of accidental overdose or prolonged use, consider fetal heart rate monitoring. |
| Fertility Effects | No data on effects on human fertility. Animal studies: No impairment of fertility observed in rats at oral doses up to 24 mg/kg/day. However, systemic sympathomimetic effects may theoretically affect reproductive function, but data are lacking. |